• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds

November 26, 2024
in Medical Research
Reading Time: 3 mins read
A A
0
Biden will move to have medicare, medicaid cover GLP-1 weight-loss meds
5
SHARES
10
VIEWS
Share on FacebookShare on Twitter


Biden will move to have medicare, medicaid cover GLP-1 weight-loss meds

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.

However, the move would have to be approved by the new Trump administration.

Right now, a law passed by Congress two decades ago prevents the Medicare and Medicaid from covering any “weight loss” drug.

Under the Biden proposal, that rule would be circumvented by calling the medications treatments for the disease of obesity and its related health issues.

“We don’t want to see people having to wait until they have these additional diseases before they get treatment,” Chiquita Brooks-LaSure, the administrator of the Centers for Medicare and Medicaid Services (CMS), told The New York Times.

Under the proposed rule, every state Medicaid program would be required to cover the cost of the medications, which currently are priced at more than $1,200 per month before any drug company discounts.

According to CMS estimates, passage of the rule would open access to the weight-loss medications to 3.4 million potential new patients under Medicare and another 4 million under Medicaid.

But the incoming Trump administration would need to sign off on the new legislation. The person tapped by the president-elect to head the Department of Health and Human Services, Robert F. Kennedy, Jr, has long been a skeptic of the drugs, asserting that weight loss should instead be tackled by healthy eating.

“If we just gave good food, three meals a day, to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight,” Kennedy told Fox News before the election.

That opinion runs counter to Dr. Mehmet Oz, the former television host who is Trump’s pick to head the CMS.

Oz, who would report to Kennedy, has been vocal in his support of GLP-1 medications, the Times noted.

The Biden administration’s proposal puts pressure on Trump and his team, who on their own may not have made such a move.

However, public support for Medicare coverage of the blockbuster meds is strong: One poll from the University of Michigan found that 76% of older Americans support such a move.

GLP-1 medications work by mimicking the action of a hormone (GLP-1) in the small intestine. This slows stomach emptying and increases a person’s feeling of fullness, helping them to eat less.

Evidence is mounting that the drugs are effective in helping users lose weight and reduce their odds for a host of health issues including diabetes, heart disease, kidney problems, fatty liver disease, arthritis, and even asthma.

However, allowing eligible patients coverage for the meds would cost Medicare $25 billion over a decade and Medicaid $11 billion, Brooks-LaSure told the Times.

It’s probable that the cost of Wegovy (made by Novo Nordisk) and Zepbound (made by Eli Lilly) would fall: The Biden administration has already passed legislation allowing Medicare to negotiate the price of Wegovy, starting in 2025.

As well, many people who have obesity also have other chronic diseases—such as diabetes or heart disease—and Medicare and Medicaid already cover the drugs for people with these conditions. The number of people who have obesity without such conditions is relatively small.

However, any rule widening access to Wegovy and Zepbound via Medicare or Medicaid to anyone struggling with obesity would be ideal, Brooks-LaSure said.

“Everybody deserves access,” she told the Times. “The more friction there is in the system—the more hoops you have to meet, all these characteristics—the harder it is for people to get the care they need.”

More information:
Find out more about GLP-1 medications at the Cleveland Clinic.

© 2024 HealthDay. All rights reserved.

Citation:
Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds (2024, November 26)
retrieved 26 November 2024
from https://medicalxpress.com/news/2024-11-biden-medicare-medicaid-glp-weight.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Biden will move to have medicare, medicaid cover GLP-1 weight-loss meds

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.

However, the move would have to be approved by the new Trump administration.

Right now, a law passed by Congress two decades ago prevents the Medicare and Medicaid from covering any “weight loss” drug.

Under the Biden proposal, that rule would be circumvented by calling the medications treatments for the disease of obesity and its related health issues.

“We don’t want to see people having to wait until they have these additional diseases before they get treatment,” Chiquita Brooks-LaSure, the administrator of the Centers for Medicare and Medicaid Services (CMS), told The New York Times.

Under the proposed rule, every state Medicaid program would be required to cover the cost of the medications, which currently are priced at more than $1,200 per month before any drug company discounts.

According to CMS estimates, passage of the rule would open access to the weight-loss medications to 3.4 million potential new patients under Medicare and another 4 million under Medicaid.

But the incoming Trump administration would need to sign off on the new legislation. The person tapped by the president-elect to head the Department of Health and Human Services, Robert F. Kennedy, Jr, has long been a skeptic of the drugs, asserting that weight loss should instead be tackled by healthy eating.

“If we just gave good food, three meals a day, to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight,” Kennedy told Fox News before the election.

That opinion runs counter to Dr. Mehmet Oz, the former television host who is Trump’s pick to head the CMS.

Oz, who would report to Kennedy, has been vocal in his support of GLP-1 medications, the Times noted.

The Biden administration’s proposal puts pressure on Trump and his team, who on their own may not have made such a move.

However, public support for Medicare coverage of the blockbuster meds is strong: One poll from the University of Michigan found that 76% of older Americans support such a move.

GLP-1 medications work by mimicking the action of a hormone (GLP-1) in the small intestine. This slows stomach emptying and increases a person’s feeling of fullness, helping them to eat less.

Evidence is mounting that the drugs are effective in helping users lose weight and reduce their odds for a host of health issues including diabetes, heart disease, kidney problems, fatty liver disease, arthritis, and even asthma.

However, allowing eligible patients coverage for the meds would cost Medicare $25 billion over a decade and Medicaid $11 billion, Brooks-LaSure told the Times.

It’s probable that the cost of Wegovy (made by Novo Nordisk) and Zepbound (made by Eli Lilly) would fall: The Biden administration has already passed legislation allowing Medicare to negotiate the price of Wegovy, starting in 2025.

As well, many people who have obesity also have other chronic diseases—such as diabetes or heart disease—and Medicare and Medicaid already cover the drugs for people with these conditions. The number of people who have obesity without such conditions is relatively small.

However, any rule widening access to Wegovy and Zepbound via Medicare or Medicaid to anyone struggling with obesity would be ideal, Brooks-LaSure said.

“Everybody deserves access,” she told the Times. “The more friction there is in the system—the more hoops you have to meet, all these characteristics—the harder it is for people to get the care they need.”

More information:
Find out more about GLP-1 medications at the Cleveland Clinic.

© 2024 HealthDay. All rights reserved.

Citation:
Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds (2024, November 26)
retrieved 26 November 2024
from https://medicalxpress.com/news/2024-11-biden-medicare-medicaid-glp-weight.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Koreatown tattoo artist charged with sexually assaulting women clients

Next Post

Companies bolster currency hedges after Trump win as tariffs loom By Reuters todayheadline

Related Posts

tablets

Urinary tract infection drug recalled

June 6, 2025
5

Asthma Sufferers Could Be at Greater Risk if Trump Cuts Health Program

June 6, 2025
6
Next Post
© Reuters. FILE PHOTO: People walk past a board with currency exchange rates with Mexico's peso and the main stock index falling after Donald Trump's victory in the U.S. presidential election, in Mexico City, Mexico November 6, 2024. REUTERS/Toya Sarno Jordan/File Photo

Companies bolster currency hedges after Trump win as tariffs loom By Reuters todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Tesla stock rebounds as Trump, Musk feud shows signs of cooling

June 6, 2025
Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

June 6, 2025
Yamal-Ronaldo set for first faceoff in Nations League final – all to know

Yamal-Ronaldo set for first faceoff in Nations League final – all to know

June 6, 2025

Morning Bid: Trump-Musk bust-up smolders

June 6, 2025

Recent News

Tesla stock rebounds as Trump, Musk feud shows signs of cooling

June 6, 2025
1
Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

June 6, 2025
2
Yamal-Ronaldo set for first faceoff in Nations League final – all to know

Yamal-Ronaldo set for first faceoff in Nations League final – all to know

June 6, 2025
3

Morning Bid: Trump-Musk bust-up smolders

June 6, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Tesla stock rebounds as Trump, Musk feud shows signs of cooling

June 6, 2025
Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

Lebanese army warns Israeli airstrikes might force it to freeze cooperation with ceasefire committee

June 6, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co